# Jacob Donoghue

> Jacob Donoghue is a physician-scientist and the co-founder and CEO of Beacon Biosignals, a Boston company applying machine learning to EEG brain data to build neurobiomarkers for psychiatric, neurological, and sleep disorders. Trained with an MD from Harvard Medical School and a PhD in neuroscience from MIT, he started Beacon in 2019 on the bet that decades of overlooked brainwave recordings could be turned into a precision-medicine engine for drug development and diagnosis. Under his leadership the company has raised over $116M, secured FDA clearance for a wearable EEG headband, acquired home sleep-testing firm CleveMed, and partnered with more than half of the world's top ten biopharma companies.

- **Role:** Co-Founder and CEO at Beacon Biosignals
- **Organizations:** Beacon Biosignals
- **Nationality:** American
- **Education:** BSc, Brown University, PhD, Neuroscience, Massachusetts Institute of Technology (MIT), MD, Harvard Medical School (Health Sciences & Technology)
- **Known for:** Co-founded and scaled Beacon Biosignals into a leading platform for AI-powered EEG analytics in CNS clinical trials., Raised over $116M in total funding, including a $86M Series B (2025) and a $27M Series A (2021)., Led development of an FDA-cleared wearable EEG headband for home-based brain measurement.

## Career timeline

- **2019** — Co-founded Beacon Biosignals with Jarrett Revels (CTO) to decode brain data for neurological, psychiatric, and sleep disorders.
- **2021** — Completed MD at Harvard Medical School; Beacon raised an oversubscribed $27M Series A led by General Catalyst.
- **2023** — Spoke at the Precision Medicine World Conference and World Medical Innovation Forum on AI diagnostics.
- **2025** — Beacon acquired CleveMed's home sleep-testing technology and raised $86M Series B, bringing total funding past $116M.

## Achievements

- Co-founded and scaled Beacon Biosignals into a leading platform for AI-powered EEG analytics in CNS clinical trials.
- Raised over $116M in total funding, including a $86M Series B (2025) and a $27M Series A (2021).
- Led development of an FDA-cleared wearable EEG headband for home-based brain measurement.
- Drove the acquisition of CleveMed to expand into at-home sleep diagnostics.
- Built partnerships with more than half of the world's top ten biopharmaceutical companies, including Takeda and UCB.

## Latest updates

- **2025-11** — Beacon Biosignals raised an $86M Series B led by Innoviva with GV, S32, Catalio, Takeda and others to build the world's largest neurodiagnostic dataset.
- **2025** — Beacon acquired CleveMed's home sleep-testing technology to expand at-home diagnostics.

## Links

- Website: https://beacon.bio
- LinkedIn: http://www.linkedin.com/in/jacob-donoghue-mdphd

---

Profile page: https://yespress.io/jacob-donoghue
Published by YesPress — https://yespress.io
Last updated: 2026-06-04